[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 641
Citations 0
Capitol Health Call
February 9, 2016

Hepatitis C Drugs Top State Medicaid Pharmaceutical Expenditures

JAMA. 2016;315(6):549. doi:10.1001/jama.2016.0166

Sovaldi, Gilead Sciences’ drug for treatment of hepatitis C, ranked among the top 5 pharmaceutical expenditures for 33 states’ Medicaid programs in 2014, according to data released recently by 2 members of the Senate Finance Committee (http://1.usa.gov/1Z0I2hM).

In 14 states, Medicaid programs spent more on Sovaldi (sofosbuvir) than on any other drug, according to the new data, released by ranking member Ron Wyden (D, Ore) and Chuck Grassley (R, Iowa) (http://1.usa.gov/1O8Grl0). Because a course of treatment costs $84 000, Medicaid programs were able to treat only 2.4% of approximately 700 000 enrollees infected with hepatitis C.

First Page Preview View Large
First page PDF preview
First page PDF preview